Medtronic (NYSE: MDT [FREE Stock Trend Analysis]) today announced the first U.S. implant of the Evera MRI(TM) SureScan^® implantable cardioverter-defibrillator (ICD) System, following U.S. Food and Drug Administration (FDA) approval for its Investigational Device Exemption (IDE) application and pivotal clinical trial protocol. Evera MRI is the first ICD system to be evaluated in the U.S. that allows for magnetic resonance imaging (MRI) scans positioned on any region of the body.
Help employers find you! Check out all the jobs and post your resume.
